title: Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.
abstract: BACKGROUND
  Patients with refractory metastatic cancer have been shown to benefit from molecular profiling of tumor tissue. The ONCO-T-PROFILE project was launched in March 2014 at the Innsbruck Medical University. Within 2 years our project aims to recruit 110 patients with stage IV cancer refractory to standard therapy. Our data presented here are based on an interim-analysis.
  
  
  METHODS
  Tumor tissue specimens were submitted for molecular profiling to the certified laboratory (Caris Life Science, USA). Druggable tumor targets were selected based on biomarker status to agents with potential clinical benefit. Clinical benefit was defined as a PFS ratio (=PFS upon treatment according to the molecular profile/ PFS upon the last prior therapy) ≥ 1.3.
  
  
  RESULTS
  As of April 2015, tumors from 50 patients have been molecularly profiled and one or more targets were detectable in 48 specimens (98%). So far, 19 (38%) patients have been treated according to their molecular tumor profile. To date, 8 (42%) patients have reached a PFS ratio of ≥ 1.3.
  
  
  CONCLUSIONS
  We could show that molecular profiling is feasible in the clinical routine. A proportion of patients might benefit from an individualized treatment approach based on molecular profiling. As a result, we will proceed to enroll patients in ONCO-T-PROFILE.
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria; Laboratory for Experimental Oncogenomics, Tyrolean Cancer Research Institute, Austria.
authors.forename: Andreas
authors.initials: A
authors.lastname: Seeber
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Guenther
authors.initials: G
authors.lastname: Gastl
authors.affiliation: Department of Pathology, Innsbruck Medical University, Austria.
authors.forename: Christian
authors.initials: C
authors.lastname: Ensinger
authors.affiliation: Haematooncological Day Hospital, Hospital of Merano, Italy.
authors.forename: Gilbert
authors.initials: G
authors.lastname: Spizzo
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Willenbacher
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Florian
authors.initials: F
authors.lastname: Kocher
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Christoph
authors.initials: C
authors.lastname: Leitner
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Ella
authors.initials: E
authors.lastname: Willenbacher
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Arno
authors.initials: A
authors.lastname: Amann
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Normann
authors.initials: N
authors.lastname: Steiner
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Eisterer
authors.affiliation: Caris Life Sciences, Basel, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Voss
authors.affiliation: Caris Life Sciences, Basel, Switzerland.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Russell
authors.affiliation: Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
authors.forename: Heinz
authors.initials: H
authors.lastname: Zwierzina
keywords: cancer; caris life sciences; molecular profiling; next generation sequencing; personalized medicine